Baxter wins FDA nod for Spectrum IQ infusion system

Baxter (NYSE:BAX) said today that it won FDA clearance for its Spectrum IQ infusion system with Dose IQ safety software.

The company touted its system as the first of its kind to include bi-directional electronic medical records integration.

“EMR integration is an important step in making infusions safer, which is why Baxter designed the Spectrum IQ system with features that simplify EMR integration and help customers overcome EMR integration adoption barriers,” Scott Luce, GM of Baxter’s U.S. hospital products business, said in prepared remarks. “These features set a new standard for medication administration, helping enhance both patient safety and clinician efficiency.”

Baxter’s Spectrum IQ pump features Line Check Notification technology, which provides a visual notification matching the pump and medication. Through its partnership with First Databank, Baxter also added a library of IV medications into its software to make the delivery of infused drugs safer.

“Creating and maintaining drug libraries used for configuring smart pumps requires substantial research and development time,” Dr. Charles Tuchinda, president of FDB, added. “Dose IQ Safety Software powered by FDB Infusion Knowledge helps save time by providing a knowledge base of suggested infusion parameters for the Spectrum IQ Infusion System, including dose limits, concentrations and durations. Integrating evidence-based practices into the clinical workflow helps facilitate improved patient safety, expedited drug library creation and efficient deployment and implementation of the Spectrum IQ pump, which helps protect more infusions.”

The Spectrum IQ pump also includes a feature designed to prevent errors due to dose or rate change. Other key properties of the infusion pump system, according to Baxter, include its built-in asset tracking application, an infusion dashboard of information designed to optimize outpatient IV billing and alarm/alert routing through alarm management systems.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Last Chance to Save for DeviceTalks Boston! Early rates for DeviceTalks Boston end August 15th. Don't miss the chance to save $100 and join top medtech innovators including leaders from Hologic, Google, Gray Matter, TransEnterix, NxStage Medical, Smith & Nephew, HeartFlow, Dynatronics, Johnson & Johnson, Allied Minds, and many more. View Full Agenda Register today to save. Use code LASTCALL to save an additional 10%.